Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance

SIMPLE SUMMARY: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine kinase oncoprotein BCR-ABL1. This led to the development of tyrosine kinase inhibitors (TKI), with Imatinib being the first TKI...

Descripción completa

Detalles Bibliográficos
Autores principales: Alves, Raquel, Gonçalves, Ana Cristina, Rutella, Sergio, Almeida, António M., De Las Rivas, Javier, Trougakos, Ioannis P., Sarmento Ribeiro, Ana Bela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508378/
https://www.ncbi.nlm.nih.gov/pubmed/34638304
http://dx.doi.org/10.3390/cancers13194820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508378/
https://www.ncbi.nlm.nih.gov/pubmed/34638304
http://dx.doi.org/10.3390/cancers13194820

Ejemplares similares